



25 November 2022

OMEGA DIAGNOSTICS GROUP PLC
(“Omega” or the “Company” or the “Group”)

Receipt of deferred consideration

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.

Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

Omega Diagnostics Group PLC

Jag Grewal, Chief Executive
Chris Lea, Chief Financial Officer

www.omegadiagnostics.com

via Walbrook PR

finnCap Ltd

Geoff Nash/Edward Whiley (Corporate Finance)
Alice Lane/ Harriet Ward (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus / Sam Allen

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893 / Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com